Pediatric pharmacotherapy

by Anker, Johannes van den Kiess, W., (Wieland) Schwab, M., (Matthias)

Type Book

Rate 0.0 /5

Details

Files

Reviews

Download

Title Statements

Full title :Pediatric pharmacotherapy / Wieland Kiess, Matthias Schwab, Johannes van den Anker, editors.

Summary

This volume provides readers with the most updated scientific information on the efficacy and safety of medicines for children and adolescents. The book enriches the understanding of pediatric pharmacotherapy for health professionals, regulatory agencies, pharmaceutical companies and learned societies. It contains important information on the pharmacodynamics and pharmacokinetics of drugs. It summarizes the latest investigations on the effects of pharmacological treatments in relation to and dependent on age, gender, fat mass and disease status. Therefore and importantly, this volume reviews the latest data on how pharmacotherapy has to be adjusted and personalized in regards to stages of development and during the pediatric lifespan from neonate through adolescence. In addition, the topic of rare diseases and special challenges for pharmacotherapy will be included and will provide readers with the necessary knowledge to handle complex diseases and treatment strategies especially in relation to pharmacotherapy of rare and orphan diseases.

Edition Statements

Publication Date:2020.

Publication Statements

Publisher(s):Springer
Place of Publication:Cham, Switzerland
Language:eng
Publication Date:2020.

The Physical Object

Description:1 online resource

Edition Identifiers

ISBN:9783030504946, 3030504948
DOI:10.1007/978-3-030-50494-6
oclc:on1176512445
LC Classification:RJ560
Dewey Decimal:615.1083

Intro -- Preface -- Contents -- Antiepileptic Drugs in Pediatrics -- 1 Evolution of Anti-seizure Medication Development -- 2 ``First-Generation ́́and ``Second-Generation ́́Antiepileptic Drugs -- 2.1 Phenobarbital -- 2.2 Phenytoin -- 2.3 Ethosuximide -- 2.4 Valproate -- 2.5 Vigabatrin -- 2.6 Zonisamide -- 2.7 Lamotrigine -- 2.8 Felbamate -- 2.9 Topiramate -- 2.10 Oxcarbazepine -- 2.11 Levetiracetam -- 3 Newest-Generation (``Third-Generation)́́ Medications -- 3.1 Pregabalin -- 3.2 Lacosamide -- 3.3 Stiripentol -- 3.4 Rufinamide -- 3.5 Eslicarbazepine Acetate -- 3.6 Perampanel

3.7 Brivaracetam -- 3.8 Cannabidiol/Epidiolex -- 3.9 Everolimus -- 4 Drugs in Development -- 4.1 Benzodiazepine Formulations -- 4.2 Bumetanide (NKCC Inhibitor) -- 4.3 Fenfluramine (Amphetamine Derivative) -- 4.4 Ganaxolone (GABAergic) -- 4.5 Huperzine -- 4.6 Ion Channel Modulators -- 4.7 Metabolic Modulators -- References -- Pharmacotherapy of Duchenne Muscular Dystrophy -- 1 Introduction -- 2 Treatment Goals in DMD: Current Landscape -- 3 Treatment Goals in DMD: Pharmacotherapies in the Pipeline -- 4 Treatment Goals in Becker Muscular Dystrophy and Female DMD Carriers -- 5 Looking Forward

3.1.1 What Doses and Inte…

Subjects

Children -- Diseases Enfants -- Maladies MEDICAL -- Pediatrics MEDICAL -- Pharmacology Paediatric medicine Pediatric pharmacology Pharmacologie pédiatrique pharmacology